Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (September 2026)
23 slides from Anixa Biosciences's investor presentation, September 2026
Slide 1: Anixa Biosciences Corporate Presentation
Aanixa BIOSCIENCES NASDAQ: ANIX September 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Anixa Snapshot
Anixa Snapshot Clinical-stage company developing first-in-class products to treat & prevent cancer Robust Strong Clinical Key Significant TAM Pipeline Data Partnerships Opportunity $$$ $ Strong Balance Clean Capital Strong Consistent Capital Efficient Sheet Table Insider Buying Business Model 3
Slide 4: Capital Efficient Business Model
Capital Efficient Business Model NASDAQ:ANIX Develop programs with partners $14M Cash and short-term investments as of July 31, 2026 o Leverage existing infrastructure of partner o Maintain low overhead and cash burn ~$5-7M Approximate annual cash burn since 2017 o Allows for multiple orthogonal p
Slide 5: Clinical Programs & Development Partnerships
Clinical Programs & Development Partnerships Advancing two clinical stage programs across two modalities, each developed with a leading research or clinical institution THERAPEUTIC MECHANISM GEOGRAPHIC UPCOMING INDICATION STAGE PARTNERS AREA OF ACTION RIGHTS MILESTONES Ovarian Periodic data CAR-T Ca
Slide 6: Ovarian Cancer Therapy Liraltagene autoleucel (lira-cel)
CAR-T Program Ovarian Cancer Therapy Liraltagene autoleucel (lira-cel) 6
Slide 7: CAR-T Procedure- Chimeric Antigen Receptor T cell
CAR-T Procedure- Chimeric Antigen Receptor T cell 7
Slide 8: CAR-T Technology: Background & Opportunity
CAR-T Technology Background & opportunity Chimeric Antigen Receptor T cell CAR- T has made great inroads in B-Cell cancers Our Opportunity High overall response rates and durable responses CAR-T in solid tumors has failed (50-80% of patients) Multi-billion-dollar valuations and big pharma deal
Slide 9: Anixa's Unique & Targeted CAR-T Approach for Solid Tumors- Lira-cel
Anixa’s Unique & Targeted CAR-T Approach for Solid Tumors- Lira-cel Exclusive worldwide license from The Wistar Institute Lira-cel for Ovarian Cancer Other CAR-T Programs Follicle Stimulating Hormone Receptor (“FSHR”)- NVS, JNJ/Legend, GILD (ACLX, KITE), BMS and mediated CAR-T technology others focu
Slide 10: Relative FSHR mRNA Expression
Relative FSHR mRNA Expression 0.0005 0.0015 0.0025 0 0.001 0.002 Adrenal Gland Brain Cerebellum Brian Whole Fetal Brain *In Healthy Humans* Colon Heart Kidney Liver Lung Placenta Prostate Salivary Gland Skeletal Muscle Spleen Thymus Thyroid Gland Trachea Uterus Only in Fetal Thymus Small Intestine S
Slide 11: Lira-cel: Dual Mechanism of Action
Lira-cel: Dual Mechanism of Action Angiogenesis Many tumors have blood vessels where FSHR Tumors induce rapid blood vessel is expressed even though healthy tissue does growth to nourish themselves not show such expression Anti-angiogenesis drugs are a multi-billion- dollar class of cancer treatm
Slide 12: Intraperitoneal Delivery (IP) Is Another Key Advantage
Intraperitoneal Delivery (IP) Is Another Key Advantage Most, if not all, ovarian cancer lesions remain within the peritoneal cavity By delivering through an IP catheter, the engineered T cells will largely remain in the peritoneal cavity o Minimizes side effects like CRS o Better trafficking to
Slide 13: Dose-escalation first-in-human clinical trial in recurrent ovarian cancer
Dose-escalation first-in-human clinical trial in recurrent/chemoresistant ovarian cancer • PI: R. Wenham, MD, Chair, Gynecologic Oncology Program, Moffitt Cancer Center • I.P. vs. I.V. Comparative safety and effectiveness Table 1. Dose-escalation scheme. Cohort Dose Level Cyclophosphamide dose FSHC
Slide 14: Lira-cel CAR-T Treatment: Recurrent Ovarian Cancer Patients
Lira-cel CAR-T Treatment: Recurrent Ovarian Cancer Patients- Sep 11, 2026 Dosage (CAR+ cells/kg) 1 x 107 PT14 +lymphodepletion Alive PT 13 Expired PT 12 3 x 106 PT 11 PT 10 PT 9 1 x 106 PT 8 PT 7 PT 6 3 x 105 PT 5 PT 4 PT 3 1 x 105 PT 2 PT 1 0 5 10 15 20 25 30 Months since Treatment 14
Slide 15: Breast Cancer Vaccine Program
Vaccine Program Breast Cancer 15
Slide 16: Breast Cancer Vaccine: Retired Tissue-Specific Protein
Breast Cancer Vaccine: Retired Tissue-Specific Protein Exclusive worldwide license from Cleveland Clinic Retired Tissue-Specific Protein α-LACTALBUMIN Expressed at periods of life, but no longer expressed as we Expressed only in the breast and only during lactation age Expressed in tumor cells,
Slide 17: Proof of Concept - Published in 2012
Proof of Concept* -Published in 2012 LITTER Vaccinated mouse After vaccination mice were mated and allowed to have a litter. The pups were perfectly normal at birth. Mothers were unable to produce milk. This proves that vaccination targeting α-Lactalbumin enables the immune system to destroy all cel
Slide 18: Pre-Clinical Studies: Vaccination Prevents Breast Cancer
Pre-Clinical Studies: Vaccination Prevents Breast Cancer •Well-Tolerated •Robust Pre-Clinical Response MMTV-neu Mice 100 80 Tumor Size (mm²) 60 40 20 0 Vaccinated Controls Vaccinated mice did not exhibit autoimmune damage, while single T 100% of α-Lactalbumin 80% of un-vaccinated mice cell infiltrat
Slide 19: Phase 1 Trial
Phase 1 Trial Conducted by Cleveland Clinic, funded by U.S. Department of Defense (DOD) An open-label Phase 1 dose-escalation trial Cohort 1a Cohort 1b Cohort 1c Design (Recurrence Group) (Prevention Group) (Treatment Group) Healthy women w/mutations Chosen to undergo Participants will 24-36 P
Slide 20: Positive Phase 1 Clinical Results
Positive Phase 1 Clinical Results All Major Endpoints Met o 35 patients dosed o 26 TNBC patients who have undergone standard of care, but are at risk of recurrence (40-80% recur in 5 years)— cohort 1a o 4 genetic risk patients choosing prophylactic mastectomies— cohort 1b o 5 patients with residual
Slide 21: Phase 2 Breast Cancer Vaccine Trial
Phase 2 Breast Cancer Vaccine Trial • Near Term- Therapeutic Approach Phase 2 trial in neo-adjuvant setting – before surgery • Faster evaluation of efficacy • Multiple types of breast cancer • Faster data, enabling earlier alliance with big pharma Two Arms • Standard of Care + Vaccine • Standard of
Slide 22: Breast Cancer Vaccine Development Plan and Market Opportunity
Breast Cancer Vaccine Development Plan and Market Opportunity • Clinical Trials and Launches will occur in stages • Neo-Adjuvant therapeutic treatment Market Opportunity • 2023- $38.35 billion1 • 2030- $89.67 billion, projected CAGR of 12.9%1 • Adjuvant therapeutic treatment Market Opportunity • Ove
Slide 23: Thank you
Thank you CONTACT INFORMATION: Amit Kumar, Ph.D. Chairman & CEO ak@anixa.com Mike Catelani President, COO & CFO mcatelani@anixa.com NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (September 2026) on 6ix